logo

Cymabay Therapeutics Inc. (CBAY)



Trade CBAY now with
  Date
  Headline
8/3/2020 7:21:58 AM CymaBay Says Positive Topline Results From ENHANCE Study For Seladelpar In Patients With Primary Biliary Cholangitis
7/23/2020 8:35:43 AM CymaBay Says Clinical Hold Lifted On Seladelpar INDs In NASH, PBC And PSC
11/25/2019 8:09:33 AM CymaBay Therapeutics Terminates Phase 2b Study Of Seladelpar
6/11/2019 7:10:42 AM CymaBay Therapeutics Reports Topline 12-Week Data From Phase 2b Study Of Seladelpar For Nonalcoholic Steatohepatitis
4/12/2019 8:19:09 AM CymaBay Therapeutics Presents Positive Phase 2 Data For Seladelpar At The International Liver Congress 2019
2/19/2019 8:10:37 AM CymaBay Therapeutics Announces Early Enrollment Of Phase 2b Study Of Seladelpar For Nonalcoholic Steatohepatitis
10/30/2018 8:05:23 AM CymaBay Begins Seladelpar Global Phase 3 Registration Study (ENHANCE)
10/3/2018 9:04:33 AM CymaBay Therapeutics Announces Additional Positive Results From Ongoing Phase 2 Study Of Seladelpar In Patients
5/8/2018 8:03:48 AM CymaBay Anounces Initiation Of Phase 2b Study Of Seladelpar In Patients With Non-Alcoholic Steatohepatitis
4/11/2018 7:50:17 AM CymaBay: Positive 12-Week, 26-Week Results From Phase 2 Study Of Seladelpar In Patients With Primary Biliary Cholangitis
1/30/2018 8:08:44 AM CymaBay Therapeutics Prices 11.6 Mln Shares At $10.80/shr